IL31 is a type 2 cytokine that activates STAT3 and possibly STAT1 and STAT5 through a heterodimeric receptor composed of IL31RA and OSMR. It functions in skin immunity and may enhance myeloid progenitor survival. IL-31 is predominantly produced by Th2 cells 1 and is recognized as a critical driver of pruritus in atopic dermatitis and other allergic diseases 2. The cytokine directly stimulates sensory neurons expressing IL31RA, particularly those coexpressing TRPV1 and TRPA1 channels 1, establishing neuro-immune communication that propagates itch sensitization in AD 3. IL-31 has also been identified as relevant for pruritus in cutaneous T-cell lymphoma 4. Clinically, IL-31 inhibition represents a validated therapeutic target: nemolizumab, an anti-IL-31 antibody, has been approved by the FDA for moderate-to-severe atopic dermatitis in patients aged 12 years and older 5. Additionally, IL-31 belongs to the IL-6 cytokine family and may modulate the tumor microenvironment in cancer contexts 6. Recent evidence suggests targeting the IL-31/IL31RA/OSMR axis may benefit inflammatory and neuroinflammatory diseases beyond AD 2.